文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

携带相似载脂蛋白AI突变(载脂蛋白AI米兰型和载脂蛋白AI巴黎型)的受试者中载脂蛋白AI和AII的代谢

Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris.

作者信息

Perez-Mendez O, Bruckert E, Franceschini G, Duhal N, Lacroix B, Bonte J P, Sirtori C, Fruchart J C, Turpin G, Luc G

机构信息

Department of Atherosclerosis, SERLIA and INSERM U325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019, Lille, France.

出版信息

Atherosclerosis. 2000 Feb;148(2):317-25. doi: 10.1016/s0021-9150(99)00279-8.


DOI:10.1016/s0021-9150(99)00279-8
PMID:10657568
Abstract

ApoAI Milano (AI(M)) and apoAI Paris (AI(P)) are mutant forms of apoAI in which cysteine is substituted for arginine at residues 173 and 151 respectively leading to the formation of homodimers and heterodimers with apoAII. Heterozygous subjects with these mutants are characterized by low levels of plasma HDL cholesterol and apoAI. The present study analyzed the metabolism of the different complexes of apoAI in three subjects, two AI(M) and one AI(P), using a primed-constant infusion of trideuterated leucine. In AI(M) carriers, the mutant form was almost equally distributed in AI(M) dimer, AI(M):AII heterodimer and the monomer, whereas, in the AI(P) subject, the mutant apoAI was essentially in the apoAI(P):AII complex. Normal apoAI was low in the AI(M) subjects (20 and 16 mg/dl) but very low in the AI(P) subject (0.3 mg/dl). In the AI(M) subjects, the low levels of apoAI were due to a rapid catabolism with a normal synthetic rate. However, the apoAI kinetics were heterogeneous with a rapid catabolism of the AI(M):AII complex (FCR of 0.430 and 0.401 day(-1)) and the AI(M) monomer (FCR of 0.570 and 0.406 day(-1)) whereas the AI(M) dimer was catabolized slowly (FCR of 0.114 and 0. 118 day(-1)). In contrast, AI(P) was catabolized relatively slowly with a FCR of 0.263, 0.182 and 0.258 day(-1) for AI(P) homodimer, apoAI(P):AII heterodimer and AI(P) monomer. In the three subjects, normal apoAI was catabolized quickly, with an FCR of 0.805 and 0.601 day(-1) in AI(M) carriers and 0.526 day(-1) in the AI(P) carrier. Therefore, the low level of apoAI in the AI(P) carrier is caused by a low production rate of apoAI, particularly of normal apoAI. In conclusion, apoAI is kinetically heterogeneous in AI(M) and in AI(P) subjects. Moreover, the two mutations lead to significant differences in the kinetic behavior of mutant apoAI depending on its inclusion in its complexes.

摘要

载脂蛋白A-I米兰型(AI(M))和载脂蛋白A-I巴黎型(AI(P))是载脂蛋白A-I的突变形式,其中分别在第173位和第151位残基上半胱氨酸取代了精氨酸,导致与载脂蛋白A-II形成同二聚体和异二聚体。携带这些突变的杂合子受试者的特征是血浆高密度脂蛋白胆固醇和载脂蛋白A-I水平较低。本研究使用氘代亮氨酸的首剂-恒速输注法分析了三名受试者(两名AI(M)携带者和一名AI(P)携带者)中不同载脂蛋白A-I复合物的代谢情况。在AI(M)携带者中,突变形式几乎均匀分布于AI(M)二聚体、AI(M):A-II异二聚体和单体中,而在AI(P)受试者中,突变的载脂蛋白A-I主要存在于载脂蛋白AI(P):A-II复合物中。AI(M)受试者中正常载脂蛋白A-I水平较低(分别为20和16mg/dl),而在AI(P)受试者中极低(0.3mg/dl)。在AI(M)受试者中,载脂蛋白A-I水平低是由于分解代谢迅速而合成速率正常。然而,载脂蛋白A-I的动力学是异质性的,AI(M):A-II复合物(分解代谢率分别为0.430和0.401天⁻¹)和AI(M)单体(分解代谢率分别为0.570和0.406天⁻¹)分解代谢迅速,而AI(M)二聚体分解代谢缓慢(分解代谢率分别为0.114和0.118天⁻¹)。相比之下,AI(P)分解代谢相对缓慢,AI(P)同二聚体、载脂蛋白AI(P):A-II异二聚体和AI(P)单体的分解代谢率分别为0.263、0.182和0.258天⁻¹。在这三名受试者中,正常载脂蛋白A-I分解代谢迅速,AI(M)携带者的分解代谢率为0.805和0.601天⁻¹,AI(P)携带者为0.526天⁻¹。因此,AI(P)携带者中载脂蛋白A-I水平低是由于载脂蛋白A-I,尤其是正常载脂蛋白A-I的产生率低所致。总之,在AI(M)和AI(P)受试者中,载脂蛋白A-I在动力学上是异质性的。此外,这两种突变导致突变载脂蛋白A-I的动力学行为存在显著差异,这取决于其在复合物中的组成情况。

相似文献

[1]
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris.

Atherosclerosis. 2000-2

[2]
Cholesterol mobilization by free and lipid-bound apoAI(Milano) and apoAI(Milano)-apoAII heterodimers.

Biochemistry. 2001-3-27

[3]
Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.

Clin Chim Acta. 2006-6

[4]
Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein.

Ann Clin Lab Sci. 2012

[5]
Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII).

Arterioscler Thromb Vasc Biol. 1997-5

[6]
In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency.

Atherosclerosis. 1997-2-10

[7]
Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers.

J Biol Chem. 1998-7-10

[8]
Moderate red wine consumption in healthy volunteers reduced plasma clearance of apolipoprotein AII.

Eur J Clin Invest. 1999-5

[9]
Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study.

J Am Heart Assoc. 2021-9-7

[10]
Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts).

J Gene Med. 2003-9

引用本文的文献

[1]
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.

Curr Atheroscler Rep. 2022-7

[2]
Primary genetic disorders affecting high density lipoprotein (HDL).

Drugs Context. 2018-9-11

[3]
Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?

Biology (Basel). 2015-1-6

[4]
Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I.

J Lipid Res. 2013-9-13

[5]
Tweaking the cholesterol efflux capacity of reconstituted HDL.

Biochem Cell Biol. 2012-5-18

[6]
Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization.

J Biol Chem. 2011-9-13

[7]
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

J Lipid Res. 2009-7

[8]
Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk?

Vasc Health Risk Manag. 2008

[9]
Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Biophys J. 2008-3-1

[10]
Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Curr Atheroscler Rep. 2007-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索